PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

Inclusion Criteria: * Agree to all the purposes of the study by signing and dating the informed consent. * Male, aged between 18 and 40 years, age disparity of each group should less than 10 years. * Body weight ≥ 50kg, and body mass index (BMI) between 18 kg/m2 and 26kg/m2 at screening. * Hemoglobin between 131g/L and 162g/L, hematocrit between 41% and 49%, and reticulocyte between 0.5% and 2%. * Transferrin saturation and serum ferritin are in the normal range. * Physical condition: vital signs, physical examination and laboratory tests ( including routine blood, biochemical tests, coagulation indicators, serum folic acid, vitamin B12, urine test, HBsAg, anti-HCV, anti-HIV, Immunoglobulin (IgA, IgM, IgG), thyroid function (T3, T4, TSH), autoantibodies), chest-X-ray, 12-lead ECG should all in normal range, or without significant clinically abnormal. Exclusion Criteria: * Presence of organic disease in heart, liver, kidney, brain; or presence of cardiovascular, pulmonary, gastrointestinal, urinary, neurological, endocrine, immunity, genitourinary or other systems disease. * Subjects with familial genetic disease, mental illness, or physical disability. * History of drug allergy. * Orthostatic hypotension, systolic blood pressure \<90mmHg. * Habitual medication, including Chinese herbal medicine. * Poor inclusion conditions (e.g. infirm). * Smoker (smoke everyday or more than 7 cigarettes per week)，alcoholics (more than 40g/day, equivalent to 100ml/day of 50 degree of white spirit). * Participate in any other drug trials as the subjects within the previous 3 months. * As blood donated within the previous 3 months, or experienced massive blood loss due to trauma or surgery. * Other conditions which in the opinion of the investigator precluding enrollment into the study (e.g. poor compliance).